A topic for discussion: Recently, we have seen evidence of anti-inflammatory benefits in neurodegeneration, a key role for calcium in models of PD, and now further evidence of alpha synuclein involvement. Could it be that we are heading for a future where multiple treatments will be required for dealing with PD? For example, a treatment to reduce the detrimental effects of aggregated alpha synuclein, a calcium blocker to reduce the stress being placed on the cells, AND an anti-inflammatory agent to quell the immune system response. Are all three of these treatment components required? And is it a mistake to clinically test each of these treatment components in isolation?